Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Notch 1 |
Clinical data | |
Other names | OMP-52M51 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6392H9862N1980O1710S50 |
Molar mass | 143410.36 g·mol−1 |
Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by OncoMed Pharmaceuticals.